Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 12/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 12/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.44 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12140384 | 0.88 | BRD4 (0.40) | — | |
| SCHEMBL27931266 | 0.84 | MTNR1A (0.51) | PARP1MTNR1AMTNR1BHSD17B2HSD17B1 | |
| SCHEMBL28705822 | 0.84 | KDM4E (0.43) | — | |
| SCHEMBL28012007 | 0.84 | MTNR1A (0.45) | PARP1MTNR1AMTNR1BHSD17B2HSD17B1 | |
| SCHEMBL27877846 | 0.82 | MTNR1A (0.44) | PARP1MTNR1AMTNR1BHSD17B2HSD17B1 | |
| SCHEMBL1007582 | 0.82 | MTNR1A (0.44) | PARP1MTNR1AMTNR1BHSD17B2HSD17B1 | |
| SCHEMBL1779795 | 0.82 | MTNR1A (0.44) | PARP1MTNR1AMTNR1BHSD17B2HSD17B1 | |
| SCHEMBL3407971 | 0.82 | CYP3A4 (0.40) | PARP1HSD17B2HSD17B1 | |
| SCHEMBL246278 | 0.81 | CA1 (0.42) | PARP1CES2CES1 | |
| SCHEMBL15550751 | 0.81 | HTR3E (0.43) | PARP1HSD17B2HSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | NR3C2, NR3C1, MC2R | PARP1 4875/4885MTNR1A 369/4885MTNR1B 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.